Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy
- 30 November 2013
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (12), 2847-2856
- https://doi.org/10.1158/1535-7163.MCT-13-0439
Abstract
Metformin is an oral biguanide commonly used for the treatment of type II diabetes and has recently been demonstrated to possess antiproliferative properties that can be exploited for the prevention and treatment of a variety of cancers. The mechanisms underlying this effect have not been fully elucidated. Using both in vitro and in vivo models, we examined the effects of metformin on endometrial tumors with defined aberrations in the PI3K/PTEN/mTOR and MAPK signaling pathways to understand metformin mechanism of action and identify clinically useful predictors of response to this agent. In vitro assays of proliferation, cytotoxicity, and apoptosis were used to quantify the effects of metformin on endometrial cancer cell lines with mutations in the PI3K/PTEN/mTOR and MAPK signaling pathways. The in vivo effects of oral metformin on tumor progression were further examined using xenograft mouse models of endometrial cancer. K-Ras localization was analyzed by confocal microscopy using GFP-labeled oncogenic K-Ras and by immunoblot following subcellular fractionation. Metformin inhibited cell proliferation, induced apoptosis, and decreased tumor growth in preclinical endometrial cancer models, with the greatest response observed in cells harboring activating mutations in K-Ras. Furthermore, metformin displaces constitutively active K-Ras from the cell membrane, causing uncoupling of the MAPK signaling pathway. These studies provide a rationale for clinical trials using metformin in combination with PI3K-targeted agents for tumors harboring activating K-Ras mutations, and reveal a novel mechanism of action for metformin. (C)2013 AACR.Keywords
Other Versions
This publication has 37 references indexed in Scilit:
- Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic CancerClinical Cancer Research, 2012
- Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancerBritish Journal of Cancer, 2012
- Regulating the regulator: post-translational modification of RASNature Reviews Molecular Cell Biology, 2011
- Ras trafficking, localization and compartmentalized signallingSeminars in Cell & Developmental Biology, 2011
- RAS Interaction with PI3K: More Than Just Another Effector PathwayGenes & Cancer, 2011
- AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK-, and PDK1-dependent activation of atypical PKCAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- Genetics of Endometrial CancersObstetrics and Gynecology International, 2010
- The Synergistic Effect of ConditionalPtenLoss and OncogenicK-rasMutation on Endometrial Cancer Development Occurs via Decreased Progesterone Receptor ActionJournal of Oncology, 2009
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- Pten Inactivation Accelerates Oncogenic K-ras–Initiated Tumorigenesis in a Mouse Model of Lung CancerCancer Research, 2008